Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

"_new">http://www.cff.org ).

About PTC124

PTC124 is an orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely stop the translation process, preventing production of a functional protein. In Phase 2a clinical trials in nonsense-mutation-mediated cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD), PTC124 has demonstrated the ability to produce protein across a variety of nonsense mutation types. Across all clinical studies to date, PTC124 has been generally well tolerated and has achieved target plasma concentrations that have been associated with activity in preclinical models. PTC124 is currently in Phase 2b development in DMD with the goal of demonstrating that increasing functional protein levels in patients with nonsense-mutation-mediated genetic disorders may provide clinical benefits.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation, the leading organization focused on curing and controlling cystic fibrosis, has invested nearly $300 million in drug research with biotech companies since 1998 to develop therapies to fight CF. As a result, the Foundation has built a drug pipeline with more than 30 promising therapies in development. Virtually all the approved CF therapies available today were made possible because of the support of the Foundation. Based in Bethesda, MD, the Foundation has 80 chapters and branch offices, and supports and accredits a nationwide network of 115 CF care centers that provide treatment and vital resources to patients and families. For more information visit http://www.cff.org

About PTC Therapeutics Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptiona
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  Mail-service and specialty pharmacies ... employers and government health plans $23.3 billion over ... the Pharmaceutical Care Management Association (PCMA). ... one of the easiest ways to reduce health ... Merritt . "Policymakers should resist efforts to restrict ...
(Date:2/26/2015)... Feb. 26, 2015 Every year many millions ... fight heart disease.  Nevertheless, year after year doctors and ... as the first test to determine the status of ... pain or not, even though that technology is over ... fact that doctors know, (while most patients do not ...
(Date:2/26/2015)... DUBLIN , Feb. 26, 2015 Research and ... addition of the "Radiation Therapy Equipment - Global ... This report analyzes the worldwide markets for ... Product Segments: Linear Accelerator, Treatment Planning Systems, and Radiation ... the US, Canada , ...
Breaking Medicine Technology:PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
... 2011 Reportlinker.com announces that a new market research report ... Products http://www.reportlinker.com/p060973/Cosmetic-Surgery-Products.html ... Demand for products used in cosmetic surgery is forecast ... 2014, when 16.1 million cosmetic procedures are expected to be ...
... 2011 Medco Health Solutions, Inc. (NYSE: MHS ... to present at the following healthcare conferences: (Logo: ... CEOs Unscripted conference taking place in New York at the ... 8:45 a.m. ET; The 29th Annual JPMorgan ...
Cached Medicine Technology:Reportlinker Adds Cosmetic Surgery Products 2Reportlinker Adds Cosmetic Surgery Products 3Medco CEO to Present at Upcoming Healthcare Conferences 2
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
(Date:2/27/2015)... Sacramento, Calif. (PRWEB) February 27, 2015 ... of liver-disease death, between four and 12 years earlier ... study from UC Davis Health System. , While previous ... ALD than other populations, the new study -- published ... -- is believed to be the first to pinpoint ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 OnChip ... (IPD), has introduced miniature, wire bondable, silicon ESD (Electrostatic ... LED markets. The ESD88NP and ... away from sensitive LED and IC products. These ... Varistors (MLV). All devices meet the requirements of ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Just a ... air for those suffering from Sjögren’s Syndrome after a ... by researchers at the University of Buffalo and Immco ... of research was to develop a new diagnostic ... the presence of new autoantibodies. Researchers aimed to develop ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Today, February 27th, ... KAJ Brothers , along with LXR Organics and ... END IT Campaign to raise awareness and promote prevention, rescue ... statistics provided by the END IT Coalition, slavery is the ... year and exists in 167 countries around the world. Slavery ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2
... drink, smoke and use drugs are influenced more by ... increase the risk of substance abuse in teenage girls, ... that risk factors for substance abuse are different in ... professor of human genetics, says in a news release.//, ...
... in soluble fibre and low in saturated fats can lower ... new study found, suggesting medication-free cholesterol control may be viable ... that a diet heavy in okra, eggplant, soy proteins, oatmeal ... LDL cholesterol levels after just one month. ,Participants ...
... week may cut their risk of Alzheimer's by more than ... that diet may affect a person's chances of developing the ... that people 65 and older who had fish once a ... those who never or rarely ate fish. The meals included ...
... has been cloned by scientists at The Scripps Research ... that detect viruses or bacteria on the surfaces of ... and bacteria into immune system responses that fight the ... of Nature, found that Trif is the topmost protein ...
... Common painkillers may lower the risk of developing Alzheimer's ... the benefit, scientists said on Friday. They reviewed 15 ... non-steroidal anti-inflammatory drugs (NSAIDs), and found people who take ... is the leading cause of dementia in the elderly. ...
... Clinic in Rochester, Minn., say they have found a ... is an allergic inflammatory reaction of the esophagus. The ... research shows a topical corticosteroid therapy is effective for ... of high levels of eosinophils. Eosinophils are a type ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: